Dr. Olga Kubassova, CEO of IAG will be speaking at the 3rd International Congress on Precision Medicine
CEO of IAG, Dr. Olga Kubassova will be speaking at the 3rd International Congress on Precision Medicine, 29-30 October 2020.
Today, Precision Medicine is much needed to optimize diseases management and recovery pathway for patients with immune-mediated inflammatory conditions and direct the growing market of new treatments. The aging populations around the world increase further pressure on society to creatively tackle the triple trillion US$ healthcare market and aging itself. PMBC2020 aims to identify and direct R&D in industry and academia towards actionable insights and the generation of flagship projects doable today to address tomorrow’s challenges.
Together with a panel of distinguished speakers, Dr. Olga Kubassova, biotech investor and the leading expert in imaging in drug development will be exploring disease-specific advances related to Precision Medicine.
This is a new event, for those who want to see beyond the state-of-the-art and truly understand what is on the horizon for drug development and patient care.
‘Growing influence of Precision Medicine will impact drug development and patient journey of tomorrow, probably beyond what we can imagine or predict today,’ said Dr. Olga Kubassova, ‘We believe that within a few years, the treatment and diagnosis of the diseases will be guided through targeted therapies; and personalized care will be an essential component of our every day life and critical step for prevention of many conditions. I am excited to be a part of the event that gives further insight how we can support the future of drug development.’
About Olga Kubassova
Dr. Olga Kubassova is a mathematician by background with MS in Mathematics from St. Petersburg State University, Russia, MS in Information Technology from Lappeenranta University of Technology, Finland and a PhD in Computer Science from the University of Leeds, UK.
Dr. Olga Kubassova is the founding scientist and CEO of IAG, Image Analysis Group, the leading imaging expert company. She started IAG straight after her PhD with an idea to bring the best of mathematics and computer science to optimize clinical development process while using imaging derived biomarkers to reliably and objectively assess efficacy of a novel drug. Today IAG is a recognized partner to many blue-chip pharma companies in rheumatology, oncology and neurology. Since completing her PhD research in the area of MRI algorithm development for musculoskeletal disorders, Olga has been a significant contributor to the development of MRI as a clinical research and diagnostic tool in rheumatoid arthritis, osteoarthritis and other inflammatory joint diseases. She has co-authored over 60 articles, 7 book chapters and a number of abstracts that have built a significant evidence base for the medical imaging as a sensitive and objective biomarker for the assessment of various diseases and as an early measure of efficacy of new drugs. Olga is an active researcher, scientific adviser to the UK government and EU funding bodies, inc. European Commission, Innovative Medicines Initiative; she is an editor and reviewer of several scientific journals.
To find out more about this conference click here.